Gainers

• iSpecimen (NASDAQ:ISPC) stock rose 44.6% to $0.19 during Thursday's after-market session. The company's market cap stands at $4.3 million.
• Simulations Plus (NASDAQ:SLP) stock increased by 13.16% to $14.7. The market value of their outstanding shares is at $261.9 million. The company's, Q2 earnings came out today.
• Wellgistics Health (NASDAQ:WGRX) shares rose 12.83% to $0.12. The company's market cap stands at $15.1 million.
• Curis (NASDAQ:CRIS) stock moved upwards by 11.09% to $0.57. The market value of their outstanding shares is at $21.8 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 7.24% to $2.22. The market value of their outstanding shares is at $1.9 million.
• Zentalis Pharmaceuticals (NASDAQ:ZNTL) stock moved upwards by 6.56% to $4.71. The company's market cap stands at $195.7 million.

Losers

• Cue Biopharma (NASDAQ:CUE) shares declined by 10.7% to $0.26 during Thursday's after-market session. The market value of their outstanding shares is at $26.7 million.
• Nexalin Technology (NASDAQ:NXL) shares fell 8.74% to $0.35. The company's market cap stands at $7.2 million.
• Onconetix (NASDAQ:ONCO) shares decreased by 7.37% to $1.13.
• Adagio Medical Holdings (NASDAQ:ADGM) stock fell 7.1% to $1.31. The market value of their outstanding shares is at $31.3 million.
• Advanced Biomed (NASDAQ:ADVB) stock declined by 7.03% to $6.22. The market value of their outstanding shares is at $8.6 million.
• SILO Pharma (NASDAQ:SILO) stock declined by 6.23% to $0.39. The company's market cap stands at $7.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.